Open Access
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Silvana Konermann,Mark D. Brigham,Alexandro E. Trevino,Julia Joung,Clea Barcena,Patrick D. Hsu,Naomi Habib,Jonathan S. Gootenberg,Hiroshi Nishimasu,Osamu Nureki,Feng Zhang,Omar O. Abudayyeh +11 more
About:
The article was published on 2016-05-22 and is currently open access. It has received 1792 citations till now. The article focuses on the topics: CRISPR.read more
Citations
More filters
Journal ArticleDOI
CRISPR/Cas9 Inhibits Multiple Steps of HIV-1 Infection.
Lijuan Yin,Siqi Hu,Shan Mei,Hong Sun,Fengwen Xu,Jian Li,Weijun Zhu,Xiaoman Liu,Fei Zhao,Di Zhang,Shan Cen,Chen Liang,Fei Guo +12 more
TL;DR: The results suggest that Cas9/gRNA is able to target and edit HIV-1 DNA both in the cytoplasm and in the nucleus, and the inhibitory effect of Cas9 on HIV- 1 is attributed to both the indels in viral DNA and the reduction in the levels of viral DNA.
Journal ArticleDOI
Reversible Disruption of Specific Transcription Factor-DNA Interactions Using CRISPR/Cas9
TL;DR: Deactivated Cas9 (dCas9) is used to disrupt binding to specific sites, a method the authors term CRISPRd since CRISpr guide RNAs are longer than transcription factor binding sites, and flanking sequence can be used to target specific sites.
Journal ArticleDOI
LncRNAs in vertebrates: advances and challenges.
TL;DR: This review focuses on the emerging understanding of lncRNAs in vertebrate animals, highlighting some recent advances in their functional analyses across several species and emphasizing the current challenges researchers face to characterize lnc RNAs and identify their in vivo functions.
Journal ArticleDOI
CRISPR/Cas9: the Jedi against the dark empire of diseases
Sehrish Khan,Muhammad Shahid Mahmood,Sajjad Ur Rahman,Hassan Zafar,Sultan Habibullah,Zulqarnain khan,Aftab Ahmad +6 more
TL;DR: In this review, an insight is provided about the recent developments using CRISPR/Cas9 against various diseases with respect to disease modeling and treatment, and what future perspectives should be noted while using this technology.
Posted ContentDOI
High-throughput discovery and characterization of human transcriptional effectors
Josh Tycko,Nicole DelRosso,Gaelen T. Hess,Aradhana,Abhimanyu Banerjee,Aditya Mukund,Mike V. Van,Braeden K. Ego,David Yao,Kaitlyn Spees,Peter Suzuki,Georgi K. Marinov,Anshul Kundaje,Michael C. Bassik,Lacramioara Bintu +14 more
TL;DR: The HT-recruit as discussed by the authors is a pooled assay where protein libraries are recruited to a reporter, and their transcriptional effects are measured by sequencing, using this approach, they measure gene silencing and activation for thousands of domains.
References
More filters
Journal ArticleDOI
Fast gapped-read alignment with Bowtie 2
TL;DR: Bowtie 2 combines the strengths of the full-text minute index with the flexibility and speed of hardware-accelerated dynamic programming algorithms to achieve a combination of high speed, sensitivity and accuracy.
Journal ArticleDOI
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li,Colin N. Dewey +1 more
TL;DR: It is shown that accurate gene-level abundance estimates are best obtained with large numbers of short single-end reads, and estimates of the relative frequencies of isoforms within single genes may be improved through the use of paired- end reads, depending on the number of possible splice forms for each gene.
Journal ArticleDOI
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
Martin Jinek,Krzysztof Chylinski,Krzysztof Chylinski,Ines Fonfara,Michael H. Hauer,Jennifer A. Doudna,Emmanuelle Charpentier +6 more
TL;DR: This study reveals a family of endonucleases that use dual-RNAs for site-specific DNA cleavage and highlights the potential to exploit the system for RNA-programmable genome editing.
Journal ArticleDOI
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina,Giordano Caponigro,Nicolas Stransky,Kavitha Venkatesan,Adam A. Margolin,Adam A. Margolin,Sungjoon Kim,Christine D. Wilson,Joseph Lehar,Gregory V. Kryukov,Dmitriy Sonkin,Anupama Reddy,Manway Liu,Lauren Murray,Michael F. Berger,Michael F. Berger,John Monahan,Paula Morais,Jodi Meltzer,Adam Korejwa,Judit Jané-Valbuena,Judit Jané-Valbuena,Felipa A. Mapa,Joseph Thibault,Eva Bric-Furlong,Pichai Raman,Aaron Shipway,Ingo H. Engels,Jill Cheng,Guoying K. Yu,Jianjun Yu,Peter Aspesi,Melanie de Silva,Kalpana Jagtap,Michael D. Jones,Li Wang,Charlie Hatton,Emanuele Palescandolo,Supriya Gupta,Scott Mahan,Carrie Sougnez,Robert C. Onofrio,Ted Liefeld,Laura E. MacConaill,Wendy Winckler,Michael R. Reich,Nanxin Li,Jill P. Mesirov,Stacey Gabriel,Gad Getz,Kristin G. Ardlie,Vivien W. Chan,Vic E. Myer,Barbara L. Weber,Jeffrey A. Porter,Markus Warmuth,Peter Finan,Jennifer L. Harris,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Michael Morrissey,William R. Sellers,Robert Schlegel,Levi A. Garraway,Levi A. Garraway +65 more
TL;DR: The results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents and the generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of ‘personalized’ therapeutic regimens.
Journal ArticleDOI
Molecular signatures database (MSigDB) 3.0
Arthur Liberzon,Aravind Subramanian,Reid M. Pinchback,Helga Thorvaldsdottir,Pablo Tamayo,Jill P. Mesirov +5 more
TL;DR: A new version of the database, MSigDB 3.0, is reported, with over 6700 gene sets, a complete revision of the collection of canonical pathways and experimental signatures from publications, enhanced annotations and upgrades to the web site.